Table 3.
Relation of clinicopathological features with TP53 and ATRX mutations in leiomyosarcoma
| TP53 mutation | ATRX mutation | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| (+) | (-) | (+) | (-) | |||
|
|
|
|||||
| N (%) | N (%) | P value | N (%) | N (%) | P value | |
| Sex | 0.006 | 0.44 | ||||
| Male | 0 (0%) | 11 (31%) | 1 (11%) | 10 (22%) | ||
| Female | 19 (100%) | 24 (69%) | 8 (88%) | 35 (78%) | ||
| Tumor site | 0.018 | 0.085 | ||||
| Uterus | 11 (58%) | 13 (37%) | 7 (78%) | 17 (38%) | ||
| Retroperitoneum | 6 (32%) | 5 (14%) | 1 (11%) | 10 (22%) | ||
| Others | 2 (11%) | 17 (49%) | 1 (11%) | 18 (40%) | ||
| Age (mean ± SD) | 54.8±10.8 | 53.1±13.9 | 0.651 | 54.46±12.9 | 53.6±12.9 | 0.651 |
| Tumor size (cm) (mean ± SD) | 12.8±5.6 | 9.1±4.0 | 0.012 | 13.4±4.1 | 10.7±.5.0 | 0.097 |
| Cell morphology | 0.840 | 1.000 | ||||
| Spindle | 13 (68%) | 23 (66%) | 6 (67%) | 30 (67%) | ||
| Epithelioid/pleomorphic | 6 (32%) | 12 (34%) | 3 (33%) | 15 (30%) | ||
| Mitotic activity | 0.302 | 0.180 | ||||
| 1-9/10 HPF | 1 (6%) | 7 (12%) | 0 (0%) | 8 (21%) | ||
| 10-19/10 HPF | 11 (65%) | 15 (52%) | 4 (50%) | 22 (56%) | ||
| >19/10 HPF | 5 (29%) | 8 (36%) | 4 (50%) | 9 (23%) | ||
| Tumor differentiation | 0.937 | 0.028 | ||||
| Well/Moderately | 10 (59%) | 18 (60%) | 2 (25%) | 26 (67%) | ||
| Poorly | 7 (41%) | 12 (40%) | 6 (75%) | 13 (33%) | ||
| Necrosis | 0.126 | 0.015 | ||||
| Absent | 1 (19%) | 7 (0%) | 0 (0%) | 8 (21%) | ||
| Present | 16 (81%) | 23 (100%) | 8 (100%) | 31 (79%) | ||
| ATRX expression | 0.167 | 0.207 | ||||
| Lost | 9 (47%) | 10 (29%) | 5 (55%) | 15 (33%) | ||
| Intact | 10 (53%) | 25 (71%) | 4 (44%) | 30 (67%) | ||
| ALT | 0.163 | 0.008 | ||||
| Negative | 5 (26%) | 16 (46%) | 0 (0%) | 21 (47%) | ||
| Positive | 14 (74%) | 19 (54%) | 9 (100%) | 24 (53%) | ||